Lacerta Therapeutics is a clinical stage gene therapy company focused on developing targeted gene delivery systems to treat genetic disorders. Their approach aims to restore normal function in affected cells, addressing the underlying causes of diseases rather than just managing symptoms.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many genetic disorders lack effective treatments that address the underlying cause of the disease. Current therapies often focus on managing symptoms rather than restoring normal cellular function. This leaves a significant unmet need for targeted and disease-modifying treatments.
Solution
Lacerta Therapeutics is developing targeted gene therapy delivery systems designed to treat the root cause of genetic disorders. Their approach focuses on delivering therapeutic genes directly to affected cells, aiming to restore normal function and provide long-term benefit. By targeting the underlying genetic defect, Lacerta's therapies have the potential to offer more effective and durable outcomes compared to traditional symptom management strategies. The company is focused on advancing its gene therapy programs through clinical development.
Target Audience
The primary target audience includes patients with genetic disorders and their families, as well as physicians and healthcare providers specializing in the treatment of these conditions.
Features
- Targeted gene delivery vectors for specific cell types and tissues
- Gene therapy constructs designed to restore normal cellular function
- Clinical-stage programs focused on genetic disorders